759415-90-2

Usage

Uses

Used in Pharmaceutical Industry:
L-Leucinol is used as a chiral building block for the synthesis of various pharmaceutical compounds. Its unique structure allows it to be a valuable component in the development of new drugs and medications.
Used in Chemical Industry:
In the chemical industry, L-Leucinol is utilized for its properties as a chiral resolving agent in chromatography. This application helps in the separation and purification of enantiomers, which are essential in the production of high-quality chemicals and compounds.
Used in Biotechnology:
L-Leucinol has potential applications in the biotechnology field, where it can be used in the development of new biological products and processes.
Used in Asymmetric Synthesis:
L-Leucinol has been studied for its potential use in asymmetric synthesis, a crucial technique in the production of enantiomerically pure compounds, which are important in the pharmaceutical and chemical industries.
Used in Metal-Catalyzed Reactions:
Additionally, L-Leucinol has been researched for its potential as a ligand in metal-catalyzed reactions, which are vital for the synthesis of complex organic molecules and materials.

Upstream product

• 951174-17-7 tert-butyl (3S,αS)-3-(N-benzyl-N-α-methylbenzylamino)-5-methylhexanoate 
• 590-86-3 isovaleraldehyde 

Downstream Products

• 64715-76-0 (S)-2-(1-hydroxy-4-methylpentan-2-yl)isoindoline-1,3-dione 

Relevant academic research and scientific papers

Novel Pyrimidine Toll-like Receptor 7 and 8 Dual Agonists to Treat Hepatitis B Virus

Toll-like receptor (TLR) 7 and 8 agonists can potentially be used in the treatment of viral infections and are particularly promising for chronic hepatitis B virus (HBV) infection. An internal screening effort identified a pyrimidine Toll-like receptor 7 and 8 dual agonist. This provided a novel alternative over the previously reported adenine and pteridone type of agonists. Structure-activity relationship, lead optimization, in silico docking, pharmacokinetics, and demonstration of ex vivo and in vivo cytokine production of the lead compound are presented.

Discovery of (S)-4-isobutyloxazolidin-2-one as a novel leucyl-tRNA synthetase (LRS)-targeted mTORC1 inhibitor

A series of leucinol analogs were investigated as leucyl-tRNA synthetase-targeted mTORC1 inhibitors. Among them, compound 5, (S)-4-isobutyloxazolidin-2-one, showed the most potent inhibition on the mTORC1 pathway in a concentration-dependent manner. Compound 5 inhibited downstream phosphorylation of mTORC1 by blocking leucine-sensing ability of LRS, without affecting the catalytic activity of LRS. In addition, compound 5 exhibited cytotoxicity against rapamycin-resistant colon cancer cells, suggesting that LRS has the potential to serve as a novel therapeutic target.

PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF VIRAL INFECTIONS

This invention relates to pyrimidine derivatives, processes for their preparation, pharmaceutical compositions, and their use in treating viral infections such as HCV or HBV.